Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Patients with this disease may exhibit various abnormalities on cranial magnetic resonance imaging (MRI), including cerebral atrophy, white matter abnormalities, hypoplasia of the corpus callosum, bilateral basal ganglia abnormalities, and symmetric necrosis of the bilateral pallidum
Reaching patients through immunology innovation: corporate presentation
More ways to better support you Cardiodiabesity & Integrated Care Learn how cardiodiabesity (the combination of cardiovascular disease, diabetes, and obesity) is becoming a health crisis and how integrated care can help
In the past, patients had a relatively limited range of procedures to consider
US$ 20.32
US$ 25.70
US$ 22.42
